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The sphingolipid metabolite sphingosine-1-phosphate
has emerged as a new bioactive molecule involved in
the regulation of cell growth, di¡erentiation, survival,
and chemotaxis as well as angiogenesis and embryo-
genesis. These e¡ects are mediated either via G-pro-
tein-coupled receptors or through intracellular actions.
The most prominent sources of sphingosine-1-phos-
phate are human platelets suggesting its potential role
in wound healing. In agreement with a positive func-
tion on reconstruction of wounded skin, we identi¢ed
sphingosine-1-phosphate as a potent chemoattractant
for keratinocytes as well as an activator of extracellular
matrix production by ¢broblasts. An unexpected ¢nd-
ing is a strong cell growth arrest of keratinocytes after
exposure to sphingosine-1-phosphate, as keratinocyte
proliferation is critical for re-epithelialization of the
wound. Most interestingly, the anti-proliferative e¡ect
of sphingosine-1-phosphate is not a result of cytotoxi-
city or apoptosis as sphingosine-1-phosphate even
protects these cells from programmed cell death.
Moreover, sphingosine-1-phosphate enhances di¡eren-
tiation of keratinocytes. To investigate further by which
signaling pathway cell growth inhibition is mediated
expression of the mRNA of all sphingosine-1-phos-
phate receptors (S1P1^5) was identi¢ed. 1 (Edg 1), 2
(Edg 5), 3 (Edg 3), 4 (Edg 6), and 5 (Edg 8) mRNA in
keratinocytes was identi¢ed. As demonstrated in gua-
nosine 5-[c-35S] triphosphate-cS binding assays, these
G-protein-coupled receptors are functional at
nanomolar concentrations. As the anti-proliferative
e¡ect of sphingosine-1-phosphate is only partially
inhibited in the presence of pertussis toxin, it was
investigated if intracellular actions are also involved.
Microinjections of sphingosine-1-phosphate in kerati-
nocytes also reduce proliferation suggesting that
both sphingosine-1-phosphate receptors as well as intra-
cellular actions mediate sphingosine-1-phosphate-
induced cell growth arrest. Key words: sphingolipids/
sphingosine/1-phosphate receptors/keratinocyte proliferation/
migration/extracellular matrix protein formations. J Invest
Dermatol 120:693 ^700, 2003
T
he bioactive sphingolipid metabolite sphingosine-1-
phosphate (S1P) plays a prominent part as a signaling
molecule to elicit a variety of physiologic and patho-
physiologic responses. In particular, S1P is involved
in the regulation of cell proliferation, di¡erentiation,
survival, and motility (Goetzl and An, 1998; Spiegel et al, 1998;
Pyne and Pyne, 2000; Spiegel and Milstien, 2000). Awell known
source of S1P are human platelets, from which it is released upon
activation by physiologic stimuli, suggesting that S1P is a signi¢-
cant factor involved in endothelial injury, in£ammation, throm-
bosis, angiogenesis, and wound healing by increasing migration
and proliferation of endothelial cells (Yatomi et al, 1997; Ruwisch
et al, 2001).
Growing interest in S1P has been increased by the discovery of
a family of distinct G-protein-coupled receptors, which origin-
ally were designated endothelial di¡erentiation gene (Edg) recep-
tors (Verlinden et al, 1998). Most recently, a nomenclature
subcommittee of the International Union of Pharmacologists
has renamed these receptors according to the binding ligand and
the order of discovery. To date, ¢ve S1P receptors and three lyso-
phosphatidic acid (LPA) receptors have been identi¢ed, which are
named S1P1 (Edg 1), S1P2 (Edg 5), S1P3 (Edg 3), S1P4 (Edg 6),
S1P5 (Edg 8); and LPA1 (Edg 2), LPA2 (Edg 4), LPA3 (Edg 7)
(Fukushima et al, 2001; Chun et al, 2002). Intracellular signaling
pathways activated by the cloned S1P receptors have been
characterized in heterologous expression systems indicating an
in£uence on cyclic adenosine monophosphate levels as well as
activation of phospholipase C, Ras, mitogen-activated protein
kinase, Rho, and several protein tyrosine kinases (An
et al, 1998; Lee et al, 1998; Okamoto et al, 1998, 1999;Van Brocklyn
et al, 1998; Zondag et al, 1998; Gonda et al, 1999).
Nevertheless, several lines of incidence indicate that S1P also
acts as an intracellular second messenger. As sphingosine kinase
is the crucial enzyme for the formation of S1P, numerous stimuli
have been identi¢ed to increase its activity and subsequent intra-
cellular S1P levels. These stimuli comprise platelet-derived
growth factor, nerve growth factor, 1a,25-dihydroxyvitamin D3
(1,25-(OH)2D3), phorbol myristate acetate, activation of the
formyl peptide receptor by N-formyl-methionyl-leucyl-
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phenylalanine, and cross-linking of the FceRI receptors by anti-
gens (Olivera and Spiegel, 1993; Mazurek et al, 1994; Choi et al,
1996; Edsall et al, 1997; Kleuser et al, 1998; Melendez et al, 1998;
Alemany et al, 1999). In agreement, inhibition of sphingosine ki-
nase activity utilizing N,N-dimethylsphingosine prevents cellular
proliferation induced by mitogenic stimuli and revokes the cyto-
protective e¡ects of protein kinase C, nerve growth factor, and
1,25-(OH)2D3 (Cuvillier et al, 1996; Edsall et al, 1997; Kleuser
et al, 1998). In addition, increase of intracellular S1P levels by
microinjection mobilizes calcium from internal stores and
induces proliferation of Swiss 3T3 cells (Van Brocklyn et al,
1998). Furthermore, sphingosine kinase has been overexpressed
in NIH 3T3 and HEK 293 cells leading to an increase of intracel-
lular S1P levels and a subsequent promotion of cell growth and
survival (Olivera et al, 1999). In these studies an export of S1P
from the cytoplasm to the extracellular space was not observed.
On the contrary in a further study it has been reported that trans-
fection of HEK 293 with sphingosine kinase leads to a constitu-
tive export of the enzyme into the extracellular environment
suggesting an external formation of S1P (Ancellin et al, 2002).
Interestingly, S1P is stored in human platelets and released at
wounded sites suggesting a positive role of this sphingolipid me-
tabolite in the process of wound healing of the skin (Lee et al,
2000). Contrary to these expectations, most recently we found
that S1P is increased in keratinocytes after treatment with those
doses of 1,25-(OH)2D3, which inhibit keratinocyte proliferation
(Manggau et al, 2001). This is of interest as a cell growth inhibi-
tory e¡ect of keratinocytes opposes re-epithelialization of the
skin. Therefore, the in£uence of S1P on critical parameters of
wound healing such as proliferation and migration of keratino-
cytes as well as proliferation and matrix formation of ¢broblasts
was investigated. In agreement with results of several ¢broblast
cell lines S1P induced proliferation of primary ¢broblasts. More-
over, matrix protein formation by S1P was observed. In keratino-
cytes S1P enhanced migration but induced a signi¢cant cell
growth arrest of human keratinocytes not due to toxic or apop-
totic e¡ects. The latter ¢nding was unexpected as inhibition of
cell growth of keratinocytes decelerates re-epithelialization of
the cutaneous barrier. Additionally, despite expression of func-
tional S1P receptors, the anti-proliferative e¡ect was also visible
after microinjection of S1P.
MATERIALS AND METHODS
Materials 1,25-(OH)2D3 was a generous gift from Leo Pharmaceuticals
(Ballerup, Denmark). [methyl-3H]Thymidine (35 Ci per mmol),
[3H]putrescine (80 Ci per mmol), [35S]guanosine 5-[y-35S] triphosphate
(GTPgS) (1000 Ci per mmol), and gelatin Sepharose 4B were purchased
from Amersham Pharmacia Biotech (Freiburg, Germany).
[35S]Methionine (1175 Ci per mmol) was from Perkin Elmer (Boston,
MA). S1P was purchased from Biomol Research Laboratory Inc.
(Plymouth Meeting, PA). Transforming growth factor (TGF)-b was from
Calbiochem (Bad Soden, Germany). Mouse monoclonal anti-human
plasminogen activator inhibitor 1 (PAI-1) and mouse monoclonal anti-
human ¢bronectin antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Dimethylcasein, putrescine, propidium
iodide, leupeptin, aprotinin, phenylmethylsulfonyl £uoride (PMSF),
sodium orthovanadate, deoxypyridoxine, bovine serum albumin (BSA),
Triton X-100, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), ethidium bromide, GIEMSA, Dulbecco’s modi¢ed
Eagle’s medium (DMEM), aprotinin, pepstatin, and leupeptin were
purchased from Sigma-Aldrich (Taufkirchen, Germany). Fetal bovine
serum was from Seromed Biochrom (Berlin, Germany). Keratinocyte
growth medium (KGM), keratinocyte basal medium (KBM), epidermal
growth factor, insulin, hydrocortisone, bovine pituitary extract,
gentamicin sulfate, and amphotericin B were purchased from Cell
Systems (St Katharinen, Germany).
Cell culture Human keratinocytes and ¢broblasts were isolated from
juvenile foreskin from surgery. Skin was incubated at 41C in a solution of
0.25% trypsin and 0.2% ethylenediamine tetraacetic acid for 20 h and
trypsinization was terminated by addition of ice-cold DMEM containing
10% fetal bovine serum. Keratinocytes were scraped from the epidermis,
washed with phosphate-bu¡ered saline (PBS) and centrifuged at 250 g
for 5 min. The pellet was resuspended in KGM that was prepared from
KBM by the addition of 0.1 ng recombinant epidermal growth factor per
ml, 5.0 mg insulin per ml, 0.5 mg hydrocortisone per ml, 0.15 mM Ca2þ ,
30 mg bovine pituitary extract per ml, 50 mg gentamicin sulfate per ml,
and 50 ng amphotericin B per ml. The remaining skin was trypsinized for
another 10 min at 371C. The enzymatic reaction was terminated by the
addition of ice-cold DMEM containing 10% fetal bovine serum.
Fibroblasts were scraped from the dermis, ¢ltered, centrifuged, and
resuspended in DMEM containing 10% fetal bovine serum. Both
keratinocytes and ¢broblasts were pooled from several donors and
cultured at 371C in 5% CO2. For all experiments only cells of the second
or third passage were used.
MTTdye-reduction assay Keratinocytes (8104 cells per well), seeded
into 24-well plates for 24 h, were incubated with test substances for 24 h at
371C in 5% CO2. After the addition of 100 ml MTTsolution (5 mg per ml)
per well, the plates were incubated for another 4 h. The supernatants were
removed and the formazan crystals were solubilized in 1 ml of dimethyl
sulfoxide. The optical density was determined at 540 nm using a scanning
microplate spectrophotometer (Multiscans Plus, Labsystems, Helsinki,
Finland).
DNA synthesis Cells (4104 cells per well) were grown in 24-well
plates for 24 h. Then medium was replaced by fresh KBM or KGM for
keratinocytes and by serum-free DMEM for ¢broblasts. Cells were
incubated with the indicated substances for 72 h and pulsed with 1 mCi of
[methyl-3H]thymidine per well. After 23 h mediumwas removed and cells
were washed twice each with PBS and ice-cold trichloroacetic acid (5%).
The precipitated material was dissolved in 0.3 M NaOH solution and
incorporated [methyl-3H]thymidine was determined in a scintillation
counter (MicroBetat Plus,Wallac Oy,Turku, Finland).
Cell cycle analysis Cell cycle analysis was performed using a cycle test
plus DNA reagent kit (Becton and Dickinson, Heidelberg, Germany).
Keratinocytes were ¢xed, RNA was digested and DNA was labeled with
propidium iodide according to the manufacturer’s instructions. Propidium
iodide staining was determined by £ow cytometry using a FACScaliburt
(Becton and Dickinson).
Transglutaminase assay Transglutaminase activity was determined by
the method described byWakita et al (1994). Cells were cultured in KGM
and incubated with the test substances for 96 h. Keratinocytes were
collected with a rubber policeman in 20 mM Tris^HCl bu¡er containing
2 mM ethylenediamine tetraacetic acid (pH 8.0) and homogenized by
freeze thawing. After centrifugation at 600 g for 10 min, 100 ml of the
supernatant were mixed with 600 ml 50 mM Tris^HCl bu¡er (pH 8.0)
containing 10 mM CaCl2, 5 mM dithiothreitol, 540 mg dimethylcasein, 1
mM putrescine, and 2.5 mCi [3H]putrescine (80 Ci per mmol). The
mixture was incubated for 1 h at 371C and the enzymatic reaction was
stopped by addition of 600 ml ice-cold trichloroacetic acid (10%). The
protein precipitate was washed three times with ice-cold trichloroacetic
acid (5%) containing 10 mM putrescine and once with ethanol (95%). The
pellet was solubilized in 200 ml 1 M NaOH solution and radioactivity was
determined in the scintillation counter.
Extracellular matrix protein assays Measurement of ¢bronectin and
PAI-1 synthesis was assayed as previously described (Wrana et al, 1992).
Brie£y, ¢broblasts (1105 cells per well) were incubated overnight in
serum-free DMEM, followed by 12 h stimulation with the indicated
concentrations of S1P. For control assays cells were stimulated with TGF-b
(2 ng per ml). Cultures were labeled with 50 mCi per ml [35S]methionine
for 4 h. For measurement of newly synthesized secreted ¢bronectin, an
aliquot of labeled media was incubated with gelatin-Sepharose in the
presence of 0.5% Triton X-100. The beads were washed once with Tris-
bu¡ered saline (50 mM Tris^HCl, pH 7.4, 150 mM NaCl), once with 0.5 M
NaCl, once with 50 mM Tris^HCl (pH 7.4), and once again with Tris-
bu¡ered saline. Fibronectin was eluated by boiling in electrophoresis
sample bu¡er containing dithiothreitol and samples were analyzed by
sodium dodecyl sulfate^gel electrophoresis. Fibronectin was identi¢ed as a
band of 250 kDa. For measurement of PAI-1 labeled cells were removed by
washing once with PBS, three times with 10 mM Tris^HCl (pH 8.0), 0.5%
sodium deoxycholate, 1 mM PMSF, once with 10 mM Tris^HCl (pH 8.0),
and once again with PBS. Matrix proteins were extracted by scraping
into electrophoresis sample bu¡er containing dithiothreitol. PAI-1 was
identi¢ed as a characteristic protein band of 45 kDa.
For western blot analysis of ¢bronectin and PAI-1, treated or control
cells were washed twice with PBS before being lyzed on ice in lysis
bu¡er (50 mM Tris^HCl, pH 8.0, 150 mM NaCl, 1 mM ethylenediamine
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tetraacetic acid, 1% Nonidet P-40, 1 mM PMSF, and 1 mg per ml each of
leupeptin, pepstatin, and aprotinin). The cell lysates were centrifuged at
12,000 g for 5 min at 41C and the supernatant was collected. Samples
were prepared in Laemmli reducing bu¡er, boiled for 10 min, and
analyzed by sodium dodecyl sulfate^gel electrophoresis. Gels were blotted
on to PDVF-membranes. After blocking with 5% nonfat dry milk
overnight at 41C membranes were incubated with the primary antibodies
(mouse monoclonal anti-human PAI-1, mouse monoclonal anti-human
¢bronectin) for 2 h. The blots were washed three times in PBS-Tween
(0.1%) followed by incubation with the secondary antibodies (rabbit anti-
mouse IgG-horseradish peroxidase, rabbit anti-mouse IgG-AP alkaline
phosphatase) for 1 h. After washing, the blots were developed according
to the manufacturer’s protocol.
Migration assay Chemotactic migration of cells in response to a
gradient of S1P or TGF-b was measured in a modi¢ed Boyden chamber
as described (Wang et al, 1999). Cells were added to the upper well of the
chamber.The lower chamber, separated by a ¢bronectin-coated membrane,
contained S1P in the indicated concentration. As control for the
chemotactic response TGF-b (1 ng per ml) was used. Cells that had
migrated through the membrane were ¢xed and stained by GIEMSA.
The migrated cells were quanti¢ed by light microscopy at a magni¢cation
of150 by counting the stained cells from four randomly selected ¢elds.
Reverse transcription and ampli¢cation by polymerase chain
reaction The mRNA of human keratinocytes or intact skin, and Jurkat
cells were isolated by QuickPrep Micro mRNA Puri¢cation Kit
(Amersham Biosciences, Freiburg, Germany) according to the
manufacturer’s instructions. Aliquots of mRNA preparation were frozen
at801C until use. One microgram of mRNA was reverse transcribed
(Superscript reverse transcriptase, Invitrogen, Karlsruhe, Germany) in the
presence of 1 pmol of a 25^30 mer oligo(dT) primer. Based upon the
nucleotide sequences of the human S1P receptors in the database,
oligonucleotide primer pairs were prepared:
S1P1: 50 -CCC AAG CTT ATG GGG CCC ACC AGC GTC CCG-30
and 50 -GCT CTA GAC TAG GAA GAA GAG TTG ACG TTG
CC-30;
S1P2: 50 -CAT TGC CAA GGT CAA GCT GT-30 and 50 -ACG ATG
GTG ACC GTC TTG AG-30;
S1P3: 5-CCC AAG CTTATG GAC ACT GCC CTC CCG-30 and 50 -
CGG GAT CCT CAG TTG CAG AAG ATC CC-30;
S1P4: 50 -ACG GGA GGG CCT GCT CTT CA-30 and 50 -AAG GCC
AGC AGG ATC ATC AG-30;
S1P5: 50 -GTG GAC TTG AGC TTC AAG AC-30 and 50 -CAC TTT
GGG GAG GAT TTG GA-30.
Polymerase chain reaction ampli¢cation was carried out in a
Thermocycler (T Gradient, Whatman Biometra, G˛ttingen, Germany)
using the Thermoprime Plus polymerase (Advanced Biotechnologies,
Columbia, MD) under the following cycling conditions: (1) 94 C for 1
min; (2) 941C for 30 s; (3) 551C for 30 s; (4) 721C for 1 min; (5) repeat of
steps 2^4 for 30 cycles; (6) 721C for 2 min; and (7) 41C for 1 s. Polymerase
chain reaction products were size-fractionated in a 2% agarose gel, and
visualized by ethidium bromide staining.
Membrane preparation and [35S]-GTPcS-binding assay Keratinocytes
were washed with ice-cold PBS, scraped in bu¡er A containing 20 mM Tris
(pH 7.4), 500 mM PMSF, 1 mg per ml each leupeptin and aprotinin, and 0.5 mg
pepstatin per ml and homogenized by passing through a 28 gauge needle 10
times. The homogenate was centrifuged for 5 min at 5000 g and the pellet
was discarded. The supernatant was spun for 40 min at 43,000 g, the
resulting pellet was resuspended in bu¡er A and frozen at 801C until use.
Ten micrograms of protein per assay were incubated for 45 min in bu¡er
B containing 20 mM Tris (pH 7.4), 5 mM MgCl2, 1 mM ethylenediamine
tetraacetic acid, 1 mM ethyleneglycol-bis-(b-aminoethylether)-N,N,N0,
N0-tetraacetic acid, 100 mM PMSF, 1 mg per ml each leupeptin and aprotinin,
0.5 mg pepstatin per ml, 3 mM guanosine diphosphate (GDP), 50 pM
[35S]-GTPgS, and indicated concentrations of S1P. The samples were rapidly
¢ltered on GF/B glass micro¢ber ¢lters (Whatman, Kent, U.K.) presoaked
in bu¡er C (20 mM Tris, pH 7.4, 10 mM MgCl2, 100 mM NaCl, 1 mM
b-mercaptoethanol). The ¢lters were washed three times with bu¡er C and
radioactivity was determined in a scintillation counter.
Microinjection and immunostaining Keratinocytes (approximately
60% con£uent) were cultured on gridded glass coverslips. Then cells
were microinjected using an Eppendorf Micromanipulator 5171 and
Microinjector 5242 (Eppendorf, Hamburg, Germany) at a pressure of 210
hPa for 0.3 s. Approximately 400 cells were microinjected cytoplasmatically
with S1P diluted in injection bu¡er (27 mM K2HPO4, 8 mM Na2HPO4, 26
mM KH2PO4, and 1mg per ml BSA pH 7.2). Texas red-conjugated dextran
(5 mg per ml) was coinjected for identi¢cation of microinjected cells. Cells
injected only with Texas red-conjugated dextran and injection bu¡er
served as a control. After microinjection of 400 cells, they were cultured
in KGM supplemented with bromodesoxyuridine (BrdU, 10 mM) for 24 h
at 371C. Then keratinocytes were ¢xed in acidic ethanol (70% in 50 mM
glycine bu¡er, pH 2.0) and stained with mouse monoclonal anti-BrdU
antibody according to the manufacturer’s instructions (Boehringer
Mannheim GmbH, Mannheim, Germany). Coverslips were mounted on
slides and ¢xed with 20% glycerol/PBS. Cell counts of nuclear BrdU
labeling were determined by a Zeiss Axiovert 100 £uorescence microscope
(Zeiss, Jena, Germany) using a triple bandpass ¢lter.
RESULTS
S1P stimulates migration but inhibits proliferation of human
keratinocytes As S1P is released from degranulating platelets at
wound sites, we have investigated its e¡ects on di¡erent
parameters of dermal and epidermal cells involved in wound
healing of human skin. In particular these parameters include
migration and proliferation of keratinocytes responsible for the
reconstruction of the cutaneous barrier as well as proliferation of
and matrix formation by ¢broblasts.
Exogenous S1P possessed no mitogenic e¡ect in primary
human quiescent keratinocytes, isolated from skin samples and
cultured in KBM. But intriguingly, S1P decreased thymidine
incorporation of proliferating keratinocytes, cultured in KGM,
in a concentration-dependent manner indicating an anti-
proliferative action in these epidermal cells. An inhibition of DNA
synthesis of more than 60% was observed at a concentration
of 10 mM S1P with an IC50 of 1 mM (Fig 1A). Direct assessment
of cell growth con¢rmed the anti-proliferative property of
10 mM S1P with a 40% inhibition of cell growth after 3 d. In
addition, DNA £ow cytometry was used to characterize the
distribution of cells in the di¡erent phases of the cell cycle. S1P
caused a concentration-dependent accumulation of cells in the
G0/G1 phase and, in agreement with the DNA-synthesis data,
decreased the percentage of keratinocytes entering the S phase.
The number of cells in the G2 compartment was relatively
una¡ected by treatment with S1P (Fig 1B).
As cell growth arrest is often connected with an increase of the
apoptotic rate it is important to mention an opposing action of
S1P, which possesses a cytoprotective e¡ect in keratinocytes in
the same concentration range as it induces cell growth arrest
Figure1. S1P inhibits cell proliferation of human keratinocytes.
Human keratinocytes were incubated with the indicated concentrations of
S1P as BSA complex (4 mg BSA per ml PBS) for 72 h and pulsed with
[3H]thymidine. Incorporation into DNAwas determined as described un-
der Materials and Methods. Data are expressed as percentage of control (un-
stimulated keratinocytes) and are the mean7SEM of results from at least
four experiments, each run in triplicate (A). For cell cycle analysis keratino-
cytes were ¢xed, RNA was digested, DNA was labeled with propidium
iodide, and staining was determined by £ow cytometry. The experiment
was repeated independently three times obtaining similar results (B).
npo0.05 and nnpo0.001 indicate a statistically signi¢cant di¡erence from
control values.
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(Manggau et al, 2001). Only higher S1P concentrations exceeding
20 mM resulted in toxic e¡ects, visible by propidium iodide
staining, MTT dye reduction, and promoted detachment of the
cells from the dishes.
Moreover, the anti-proliferative e¡ect was accompanied by
the induction of the di¡erentiation process. Measurement of
transglutaminase activity, the crucial enzyme for the formation
of the corni¢ed envelope, indicated that S1P promotes
di¡erentiation to corneocytes (Fig 2A).
Previous data have shown that S1P generally has mitogenic
actions and moreover is a positive regulator of human
endothelial wound closure. For this reason it was surprising that
S1P inhibits keratinocyte cell growth and consequently the
re-epithelialization of the cutaneous barrier, which is a critical
factor during this process.
As keratinocyte migration is another pivotal component of
skin wound healing and S1P is a well known chemoattractant
in a variety of cells, its chemotactic potency on primary
keratinocytes was determined in a modi¢ed Boyden chamber
with ¢bronectin-coated ¢lters. Indeed, S1P was identi¢ed
as a potent factor to stimulate keratinocyte cell migration.
The chemotactic response was enhanced in a concentra-
tion-dependent and saturable manner. The EC50 value for S1P
was estimated to be 100 nM. The S1P-induced migration was
comparable with that of TGF-b1 (1 ng per ml), a potent
chemoattractant for keratinocytes (Fig 2B).
S1P induces proliferation of and matrix formation by
primary ¢broblasts In several cell lines such as Swiss 3T3
¢broblasts or rat ¢broblasts S1P has been identi¢ed as an
e¡ective mitogenic agent. Indeed, a similar e¡ect was measured
in primary ¢broblasts isolated from the same skin samples as
keratinocytes. S1P signi¢cantly increased DNA synthesis in a
concentration-dependent manner with an EC50 of 1 mM, which
is in accordance to the concentration of the cell growth
inhibitory e¡ect in keratinocytes. S1P in a concentration of
10 mM induced a 4-fold increase of thymidine incorporation in
nascent DNA (Fig 3A). Cell cycle analysis revealed that S1P
increased the proportion of cells in the S-phase, whereas the
number of cells in the G0/1 phase was reduced. These results
indicate that S1P may stimulate or inhibit cell proliferation
depending on whether the target is a ¢broblast or a
keratinocyte.
The homeostasis of di¡erent extracellular matrix proteins
in£uences the process of wound healing. Two positive
cooperative regulators are ¢bronectin and PAI-1, which are
probably critical to the motile process and the resulting tissue
plasticity. To the best of our knowledge until now an in£uence
of S1P on matrix protein generation has not been examined.
Therefore the synthesis and accumulation of ¢bronectin and
PAI-1 in cells, respectively, in medium were measured in
response to S1P using either radioactive labeling or western blot
analysis. As shown in Fig 3 (B,C) synthesis of both ¢bronectin
and PAI-1 was induced following treatment with S1P. The
accumulation of PAI-1 was concentration dependent, the
generation of PAI-1 started at 0.1 mM S1P, a maximal formation
was observed with a concentration of 10 mM of S1P. In contrast,
¢bronectin generation started also after exposure to 0.1 mM of
S1P but could not be increased using higher S1P concentrations
(Fig 3B,C).
Characterization of receptors for S1P in human
keratinocytes To characterize further and to examine whether
the unexpected anti-proliferative action of S1P in keratinocytes is
mediated through speci¢c S1P receptors, the expression of these
receptors in the epidermal cells was investigated.
Reverse transcription-polymerase chain reaction revealed that
transcripts of mRNA for all known S1P receptors, namely S1P1
Figure 2. S1P enhances di¡erentiation and migration of human
keratinocytes.Transglutaminase activity as di¡erentiation marker was de-
termined as described in Materials and Methods. Cells were cultured for 96 h
in the presence of 1,25-(OH)2D3 100 nM as positive control or with the in-
dicated concentrations of S1P delivered as BSA complex (4 mg BSA per ml
PBS).Values are expressed as percentage of control (unstimulated cells) and
are the mean7SEM of results from at least three experiments, each run in
triplicate (A). Chemotactic migration of keratinocytes in response to a gra-
dient of S1P orTGF-b as positive control was measured in a modi¢ed Boy-
den chamber as described. Data are presented as a percentage of control and
are the mean7SEM of results from at least four experiments. Each run was
done using triplicate wells (B). npo0.05 and nnpo0.001 indicate a statisti-
cally signi¢cant di¡erence vs unstimulated control cells.
Figure 3. S1P enhances proliferation of primary ¢broblasts and ma-
trix protein formation by ¢broblasts.Human ¢broblasts were incubated
with the indicated concentrations of S1P, pulsed with [3H]thymidine and
incorporation into DNAwas determined as described.Values are presented
as percentage of control (unstimulated ¢broblasts) and are the mean7SEM
of results from at least four experiments, each run in triplicate (A). Mea-
surement of the matrix proteins ¢bronectin and PAI-1 was assayed as de-
scribed. For control assays cells were stimulated with TGF-b (2 ng per ml).
Radiolabeled ¢bronectin was identi¢ed as a band of 250 kDa and labeled
PAI-1 as a characteristic protein band of 45 kDa (B).Western blot analysis
con¢rmed ¢bronectin and PAI-1 formation after treatment with S1P (C).
Similar results were obtained in three independent experiments. npo0.05,
nnpo0.001.
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(Edg 1), S1P2 (Edg 5), S1P3 (Edg 3), S1P4 (Edg 6), and S1P5 (Edg
8) are present in cultured keratinocytes (Fig 4A). To exclude that
the receptor expression is an artifact of culture, the expression
pro¢le was also demonstrated in intact skin con¢rming the
existence of S1P1^5 (Fig 4A). To evaluate coupling of S1P
receptors to G proteins the GDP/GTP exchange was measured
by the use of [35S]-GTPgS, which measures GDP/GTP exchange
of the a-subunit of the G-protein and, therefore, the initial steps
of G-protein activation by a receptor ligand. Optimal conditions
were de¢ned and S1P-induced GDP/GTP exchange was
determined. Indeed, S1P enhanced binding of [35S]-GTPgS to
G-proteins of isolated membranes in a concentration-dependent
manner with an EC50 of 5 nM indicating that human kera-
tinocytes express S1P receptors, which are functionally coupled
to G-proteins (Fig 4B). It should be mentioned that the
estimated EC50 value is in agreement with the reported Kd of
S1P for its receptors. Furthermore, we investigated the coupling
of S1P receptors in the presence of pertussis toxin (PTX), which
inactivates the a-subunit of Gi/G0 maintaining them in a
nondissociated form. Treatment with PTX resulted in a right
shift of the binding curve indicating that the stimulatory e¡ect
of S1P on [35S]-GTPgS binding is mediated by both PTX-
sensitive and PTX-insensitive G-proteins.
Microinjection of S1P induces cell growth arrest of human
keratinocytes To examine whether the anti-proliferative
property and the di¡erentiation inducing e¡ect of S1P in
keratinocytes are mediated by the binding of S1P to its
receptors, cells were treated with S1P in the presence of PTX.
Indeed, preincubation of keratinocytes with PTX caused only a
Figure 4. Expression and characterization of S1P receptors in hu-
man keratinocytes. The mRNA of cultured keratinocytes or intact skin
was isolated, reverse transcribed, and ampli¢ed as described inMaterials and
Methods. Polymerase chain reaction products of cultured keratinocytes (left
band) and intact skin (right band) were size-fractionated in an agarose gel,
and visualized by ethidium bromide staining (A). Membranes from human
keratinocytes were examined for [35S]-GTPgS binding assays in the pre-
sence of the indicated S1P concentrations with or without PTX (3 ng per
ml) preincubation for 3 h as described (B).
Figure 5. Exogenous S1P-treatment as well as microinjection of
S1P into keratinocytes decreases DNA synthesis. Human keratino-
cytes were pretreated with 3 ng PTX per ml for 3 h or vehicle and incu-
bated with the indicated concentrations of S1P for 72 h and pulsed with
[3H]thymidine. Incorporation into DNAwas determined as described un-
der Materials and Methods. Data are expressed as percentage of control
(mean7SEM) of four experiments, each run was performed in triplicate
(A). Human keratinocytes were microinjected with vehicle or S1P. Micro-
injected cells were visualized by Texas red £uorescence and BrdU incor-
poration by green £uorescein isothiocyanate using a triple band pass ¢lter.
Microinjection was also performed after preincubation of keratinocytes
with 3 ng PTX per ml for 3 h. Values (mean7SD) are the percentage of
cells positive for BrdU staining and correspond to the average of three
measurements in which 100 cells were scored. Similar results were obtained
in three independent experiments (B). npo0.05, nnpo0.001.
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partially inhibition of the anti-proliferative e¡ect induced
by S1P (Fig 5A). In analogy, PTX pretreatment diminished
S1P-induced transglutaminase activity by only 40%. These
results suggest that either PTX-insensitive S1P receptors or
intracellular targets are also involved in the anti-proliferative and
di¡erentiation inducing properties of S1P. Moreover, the fact that
the IC50 of S1P to inhibit proliferation and to induce
di¡erentiation are almost 200 times higher than the EC50 to
stimulate [35S]-GTPgS binding leads to the assumption that
these properties of S1P are due to intracellular actions rather
than binding to a cell surface receptor despite their functional
active expression. In view of this controversy it was of interest
to examine the proliferation of keratinocytes whose intracellular
levels of S1P are increased. Therefore, S1P was microinjected into
the cytosol of keratinocytes together with Texas red-conjugated
dextran to identify microinjected cells and the incorporation of
BrdU into DNA was examined 24 h later. Using double
immuno£uorescence to visualize injected cells and BrdU
incorporation, it is clearly demonstrated in Fig 5 that DNA
synthesis decreased after S1P microinjection, as only 7% of S1P-
injected cells were positive for BrdU incorporation compared
with 25% of control cells in the same ¢eld (Fig 5).
Microinjection of Texas red-conjugated dextran alone had no
signi¢cant e¡ect on DNA synthesis. As uninjected cells adjacent
to S1P-microinjected cells showed no signi¢cant decrease in
BrdU incorporation it can be excluded that S1P is leaking from
microinjected cells acting in an autocrine mechanism. To exclude
further an autocrine mechanism of S1P, microinjection was
performed in the presence of PTX. The anti-proliferative e¡ect
of S1P was insensitive to PTX treatment con¢rming that
reduction of DNA synthesis by microinjected S1P does not
require at least interaction with a PTX-sensitive G-protein-
coupled S1P receptor. Collectively, these results strongly suggest
that there is a complex interplay between cell surface receptor
signaling and intracellular targets for S1P to mediate cell growth
arrest of keratinocytes.
DISCUSSION
Cutaneous wound healing, a dynamic process that combines
tissue regeneration events with local activation of immune
functions, involves diverse cell types. These cells include
keratinocytes for the regeneration of the cutaneous barrier, ¢bro-
blasts for the production of extracellular matrix proteins, and
monocytes for the defeat of infections. Proliferation and migra-
tion of human keratinocytes is crucial for the re-epithelialization
of the cutaneous barrier. Here we report, that the e¡ects of S1P
are paradoxical concerning these parameters: keratinocyte migra-
tion is potently enhanced, whereas keratinocyte proliferation is
strongly inhibited. These ¢ndings were unexpected in some re-
spects: ¢rst, the anti-proliferative observation is in contrast to
the generally known growth promoting e¡ect of S1P, and further
on, in contrast to the suggested role of S1P in wound healing as
inhibition of cell growth of keratinocytes prevents e⁄cient clo-
sure of the wound. But it has to be considered that a variety of
mediators are released from platelets at the wounded site. Growth
factors such as epidermal growth factor, platelet-derived growth
factor, TGF-b, and ¢broblast growth factor are stored or formed
in thrombocytes, many of them a¡ect keratinocyte cell function
allowing a complex interplay (Piazza et al, 1995). Moreover, our
data indicate that the migration response of keratinocytes is more
sensitive to S1P than the cell growth inhibitory e¡ect. Thus, it
depends on the S1P levels present in a cutaneous wound, whether
cell growth inhibition and di¡erentiation will be in£uenced by
S1P. But it should be mentioned that di¡erentiation of keratino-
cytes is also a crucial event to reconstruct the cutaneous barrier. It
could also be possible that S1P may have disparate e¡ects on
di¡erent keratinocyte populations. For instance, perhaps S1P
enhances migration of stem and transit amplifying cells, but sti-
mulates di¡erentiation and inhibits proliferation of late stage
transit amplifying cells.
The stimulation of cell growth is a well established biologic
response to S1P in a variety of ¢broblast cell lines (Zhang et al,
1991; Olivera and Spiegel, 1993; Gomez-Munoz et al, 1994; Born-
feldt et al, 1995; Olivera et al, 1999). Consistent with these studies
we found a profound proliferative action of S1P in primary
human ¢broblasts isolated from the same origin as keratinocytes
indicating a bimodal e¡ect of S1P on cell proliferation depending
on the cell type. Until now an anti-proliferative e¡ect of S1P has
only been described in human myo¢broblasts (Davaille et al,
2000). In these cells, S1P rapidly increased prostaglandin E2 pro-
duction and in turn cyclic adenosine monophosphate, both have
been recognized as growth inhibitory messengers for human
myo¢broblasts.
Moreover, the presented results show signi¢cant di¡erences of
S1P on crucial parameters of endothelial and cutaneous wound
healing. S1P at low concentrations enhances migration of both
endothelial cells and keratinocytes. If the concentration is in-
creased, S1P in£uences also proliferative events in endothelial
and epidermal cells. But as S1P increases the proliferation rate of
endothelial cells, there is an opposing action in keratinocytes (Lee
et al, 2000).
The cell growth inhibitory e¡ect in keratinocytes is consistent
with our preliminary studies indicating that 1,25-(OH)2D3, at
least in concentrations higher than 1 nM, in analogy to S1P is an
anti-proliferative agent and enhances S1P levels in these epi-
dermal cells (Manggau et al, 2001). Moreover, both S1P and
1,25-(OH)2D3 possess cytoprotective actions in keratinocytes
indicating that their anti-proliferative properties are not due to
cytotoxicity (Cuvillier et al, 1996; Manggau et al, 2001).
Although it is unusual for an e¡ector to both stimulate and
inhibit cell growth it is not unprecedented. TGF-b is in analogy
to S1P a strong inhibitor of keratinocyte proliferation, but
enhances proliferation of ¢broblasts as well as activation of extra-
cellular matrix production by ¢broblasts (Alexandrow and
Moses, 1995; O’Kane and Ferguson, 1997). Moreover it is a very
potent chemoattractant and an inducer of its own production in
monocytes (Massague, 1998). Interestingly, whereas the e¡ects
of TGF-b on ¢broblast proliferation and its e¡ect to induce
chemotaxis are consistent with a positive role in wound healing,
the growth inhibitory e¡ect on keratinocytes is not. Indeed,
studies of wound healing in mice, in which the TGF-b gene has
been deleted by homologous recombination, revealed that the
release of the growth factor from degranulating platelets or secre-
tion by in¢ltrating macrophages and ¢broblasts is not critical to
initiation or progression of tissue repair. Surprisingly, no impair-
ment in wound healing was seen in TGF-b1 null mice. Instead
wounds showed an overall reduction in the amount of granula-
tion tissue and an increased rate of epithelialization compared
with littermate controls suggesting that endogenous TGF-b may
actually retard wound closure (Koch et al, 2000). In analogy to
S1P, it has also been shown that 1,25-(OH)2D3 promotes TGF-b
synthesis in human keratinocytes and originates an autocrine/
paracrine loop, which is partly responsible for the anti-prolifera-
tive action of 1,25-(OH)2D (Heberden et al, 1998).
A major point of this study was to identify whether the unex-
pected anti-proliferative e¡ect in keratinocytes is linked to an in-
tracellular e¡ect or to its plasma membrane receptors. It seems
likely that many, but not all events, are the result of S1P interac-
tion with its G-protein-coupled receptors. In Swiss 3T3 ¢bro-
blasts, however, S1P was ¢rst proposed as a second messenger
involved in the proliferative e¡ect of growth factors such as plate-
let-derived growth factor or serum, which enhance sphingosine
kinase activity and increase intracellular S1P levels (Olivera and
Spiegel, 1993). Moreover, competitive inhibitors of sphingosine
kinase block some of the proliferative signals elicited by those
growth factors (Edsall et al, 1997; Kleuser et al, 1998; Alemany
et al, 1999). But it should be mentioned that in Swiss 3T3 ¢bro-
blasts the proliferative response to exogenously added S1P is
partially sensitive to PTX, suggesting at least the potential
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involvement of G-protein-coupled receptors (Goodemote et al,
1995). Thus, it seems possible that there is a complex interplay
between cell surface receptor signaling and intracellular S1P for-
mation. Indeed, recently in HEK293 cells it has been shown that
stimulation of S1P receptors results in the activation of sphingo-
sine kinase leading to an intracellular increase in S1P (Meyer zu
Heringdorf et al, 2001).
Although we have identi¢ed functional acting S1P receptors in
keratinocytes several lines of evidence suggest that the anti-pro-
liferative e¡ect of S1P in human keratinocytes is not only
mediated by binding of S1P to its receptors. Cell growth arrest
of keratinocytes requires micromolar concentrations of S1P,
whereas putative receptor-mediated e¡ects of S1P have been
shown to occur in the nanomolar range. This is consistent with
the proliferative action of S1P in NIH 3T3 ¢broblasts and HEK
293 cells. Moreover, when S1P was microinjected in keratinocytes
BrdU incorporation revealed that S1P microinjection induces a
decrease of the proliferation rate of keratinocytes in the same ex-
tent as exogenously added S1P. This result was even con¢rmed in
the presence of PTX. Moreover, as uninjected cells adjacent to
S1P microinjected cells showed no signi¢cant decrease in BrdU
incorporation, it is unlikely that S1P is leaking from the pipette.
These data demonstrate that besides S1P-induced receptor stimu-
lation intracellular targets of S1P may contribute to the anti-
proliferative property of S1P in keratinocytes. But, although
microinjection bypasses cell surface receptors, it cannot be
excluded that S1P is transported into the extracellular medium
acting in an autocrine fashion via PTX-insensitive coupled S1P
receptors.
In summary this study indicates a dual e¡ect of S1P on para-
meters in wound healing. In fact, S1P is brought to the wound
site by the massive degranulation of platelets and therefore has
been implicated to reinforce re-epithelialization. Our ¢ndings,
in particular cell growth arrest of keratinocytes, interfere with a
rapid wound repair. Moreover, the anti-mitogenic e¡ect mediated
by S1P may be important to prevent excessive proliferation of the
skin. Owing to this property, it would be of interest to determine
whether S1P is a promising candidate in the therapy of hyperpro-
liferative skin diseases such as psoriasis vulgaris. As we recently
identi¢ed (Manggau et al, 2001) that 1,25-(OH)2D3, which is used
for the treatment of psoriasis vulgaris, enhances S1P levels in ker-
atinocytes, it seems likely that some actions of secosteroid is via
the formation of this sphingolipid metabolite.
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